Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Thanks. Positives: Low cost vs CAR-T. Quick manufacturing vs CAR-T. Not a single case of cytokine release syndrome vs CAR-T whereas CAR-T has killed patient. NOT genetically engineered like CAR-T and (RNAI, MRNA, CRISPR). Free beneficial epitope spreading. Peter Hoang is GONE.
Crazy low market cap when other tiny bio's as I mentioned have MUCH larger market caps with less, which to me just means a lot more upside potential.

NK. I have followed NK cell bio's for many years now. AFMD, FATE, NKTX, LPTX, etc.
It seems the main problem with NK cells versus T cells is longevity, or the lack of it.
NK cells live a few days to a couple of weeks. B cells for several weeks. T cells for many months or longer.
Or at least that is my general understanding of immune cells.